MedTrace Logo

Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Dermatologists

NCT00293709 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 129

Last updated 2014-02-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety profile and the effectiveness of etanercept under usual care settings in patients with PsA treated by dermatologists.

Conditions

  • Arthritis, Psoriatic
  • Psoriasis
  • Skin Diseases, Papulosquamous

Interventions

DRUG

etanercept

The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2013-02-28
Completion
2013-02-28

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00293709 on ClinicalTrials.gov